Mariette Giannini, Giulia Campione, Lea Torcq, Sylvain Donadelli, Maroua Bencheikh, Sophia Bounaud, Sandrine Jeanpierre, Kevin Geistlich, Veronique Maguer-Satta, Sylvain Lefort, Julie Leca
5 min
The bone marrow (BM) niche is a complex microenvironment essential for hematopoiesis, yet traditional 2D cell cultures fail to capture its structural and functional diversity. This study aimed to develop a standardized 3D human bone marrow model (3D-BOM) capable of recapitulating the native niche architecture, supporting long-term hematopoietic stem cell (HSC) maintenance, and providing a platform to study the dynamic interactions between stromal, endothelial, and immune cells in both healthy and leukemic (AML) contexts.
The authors constructed the 3D-BOM using self-assembled human mesenchymal stromal cells (MSCs) and endothelial cells. They validated the model by introducing THP-1 monocytic cells and iPSC-derived macrophages to assess their differentiation and polarization status. Furthermore, they incorporated primary CD34+ hematopoietic progenitors from AML patients and healthy donors. The researchers utilized single-cell RNA sequencing (scRNA-seq) to characterize the heterogeneity of the stromal and endothelial compartments and performed long-term serial culture experiments to evaluate the preservation of stemness and niche functionality.
The 3D-BOM model successfully mimics the human bone marrow microenvironment, showing that immune cells spontaneously acquire pro-inflammatory features in 3D without exogenous chemical stimuli, unlike in 2D cultures. Single-cell analysis revealed that the model supports distinct, biologically relevant stromal clusters (including MSCs, osteoblasts, and chondrocyte progenitors) and functional endothelial subpopulations (sinusoidal and type S). Importantly, the model supports the long-term culture of primary hematopoietic progenitors, maintaining their stemness over serial passages. Additionally, the presence of AML cells induced observable remodeling of the endothelial and macrophage compartments, mirroring clinical observations of increased angiogenesis and altered immune phenotypes in leukemia patients.
This 3D-BOM model provides a robust, human-relevant platform for investigating the cellular crosstalk that drives hematological malignancies. By overcoming the limitations of murine models and 2D cultures, it offers a powerful tool for studying disease progression, testing therapeutic responses, and understanding how the bone marrow niche influences hematopoietic stem cell fate in both physiological and pathological states.
Alex: How does the cancer actually use them?
Sam: Normally, monocytes act as guards—they're supposed to detect and attack threats. But when leukemia cells are present in this 3D environment, those guards shift their behavior. They start producing molecules that quiet the immune response rather than amplify it. Instead of sounding the alarm, they help the cancer stay hidden. Scientists call this shift "inflammatory polarization"—imagine a dial that can be turned toward "attack mode" or "stand down mode." The leukemia is effectively turning that dial toward stand down.
Alex: So the cancer isn't just hiding—it's actively recruiting the immune system to protect it.
Sam: That's the picture the evidence paints. And crucially, the 3D-BOM is what makes it possible to observe this. By using actual cells from patients, the researchers showed the model captures the messy, complicated interactions of real disease. They used a technique called single-cell transcriptomics—essentially a way of reading the activity of thousands of individual cells at once—to map how these cells communicate. What they found mirrors what you'd see in a patient biopsy.
Alex: Does the cancer also change the physical structure of its environment, not just the immune cells?
Sam: It does. When leukemia cells were added to the model, the cells responsible for forming blood vessels grew more aggressively. That matches what researchers see in patient tissue samples, where the cancer actively remodels its surroundings to better support its own survival. It's a clear sign the model is capturing real disease behavior, not just a simplified version of it.
Alex: So the environment isn't just a backdrop—it's an active participant in how the disease progresses.
Sam: That's the key insight. Studying the cancer cell in isolation misses the point. The leukemia and its surroundings are in constant conversation, and the 3D-BOM gives researchers a way to listen in on that conversation under controlled conditions. That's what makes it a meaningful step forward—it moves us from static, oversimplified snapshots toward something that actually reflects the complexity of living human tissue.
Alex: And if you can observe those interactions, you can potentially find ways to disrupt them.
Sam: Precisely. If you can watch how the cancer builds its bunker—how it recruits immune cells, remodels blood vessels, and creates a protective shield—you have a much better target for designing treatments. The hope is that models like this will help researchers identify the weak points in that system that chemotherapy alone can't reach.
Alex: That's a sobering reminder of how much the context around a cancer cell matters—not just the cell itself. Thanks for walking us through it, Sam, and thanks to everyone listening to ResearchPod.